WS35

WS35: sourced facts only. name: "Through rational drug design, we discovered WS35─a potent dual PTPN2/1 inhibitor exhibiting exceptional enzymatic activity (PTPN2 IC50 = 5.8 nM, PTPN1 IC50 = 12.8 nM), favorable safety profiles, and enhanced oral bioavailability (F = 7.1%)." [PMID:41047545]; target: "Through rational drug design, we discovered WS35─a potent dual PTPN2/1 inhibitor exhibiting exceptional enzymatic activity (PTPN2 IC50 = 5.8 nM, PTPN1 IC50 = 12.8 nM), favorable safety profiles, and enhanced oral bioavailability (F = 7.1%)." [PMID:41047545]; developer: "State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China." [PMID:41047545]; stage: "In B16-OVA syngeneic models, WS35 monotherapy and its combination with an anti-PD-1 antibody achieved robust tumor growth suppression, outperforming AC484, with no observable systemic toxicity." [PMID:41047545]